Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: Double-blind randomized proof of concept study

Inflammatory Bowel Diseases

Volumn 20, Issue 11, 2014, Pages 2004-2012

  Pontes, Caridad ^a   Vives, Roser ^a   Torres, Ferran ^a   Panés, Julián ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Clinical trial; Dersalazine sodium; PAF antagonist; Randomized; Ulcerative colitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; DERSALAZINE; GAMMA GLUTAMYLTRANSFERASE; MESALAZINE; PLACEBO; AMINOSALICYLIC ACID DERIVATIVE; AZO COMPOUND; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; COLON BIOPSY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; INGUINAL HERNIA; LIVER FUNCTION TEST; MALE; OPEN STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; UREA NITROGEN BLOOD LEVEL; ADOLESCENT; AGED; COLITIS, ULCERATIVE; COMPARATIVE STUDY; FOLLOW UP; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZO COMPOUNDS; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MESALAMINE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925617201     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000166     Document Type: Article

References (23)

1. Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice Guidelines in Adults: American College of Gastroenterology, practice parameters Committee. Am J Gastroenterol. 2010;105:501-523.
2. Meier J, Sturm A. Current treatment of ulcerative colitis. World J Gastroenterol. 2011;17:3204-3212.
3. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: current management. J Crohns Colitis. 2012;6:991-1030.
4. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657.
5. Faubion WJ, Loftus EJ, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-260.
6. Eliakim R, Karmeli F, Razin E, et al. Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone. Gastroenterology. 1988;95:1167-1172.
7. Nassif A, Longo WE, Mazuski JE, et al. Role of cytokines and plateletactivating factor in inflammatory bowel disease. Implications for therapy. Dis Colon Rectum. 1996;39:217-223.
8. Stack WA, Jenkins D, Vivet P, et al. Lack of effectiveness of the plateletactivating factor antagonist SR27417A in patients with active ulcerative colitis: a randomized controlled trial. The Platelet Activating Factor Antagonist Study Group in ulcerative colitis. Gastroenterology. 1998;115:1340-1345.
9. Carceller E, Salas J, Merlos M, et al. Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity. J Med Chem. 2001;44:3001-3013.
10. Gálvez J, Garrido M, Merlos M, et al. Intestinal anti-inflammatory activity of UR-12746, a novel 5-ASA conjugate, on acute and chronic experimental colitis in the rat. Br J Pharmacol. 2000;130:1949-1959.
11. Gálvez J, Garrido M, Rodríguez-Cabezas ME, et al. The intestinal antiinflammatory activity of UR-12746S on reactivated experimental colitis is mediated through downregulation of cytokine production. Inflamm Bowel Dis. 2003;9:363-371.
12. Camuesco D, Rodríguez-Cabezas ME, Garrido-Mesa N, et al. The intestinal anti-inflammatory effect of dersalazine sodium is related to a downregulation in IL-17 production in experimental models of rodent colitis. Br J Pharmacol. 2012;165:729-740.
13. Fernández-Deamo N, Solans A, Pontes C, et al. P083: tolerability, pharmacokinetics and metabolism of dersalazine sodium in healthy volunteers. J Crohns Colitis. 2010;4:S46.
14. Fernández-Deamo N, Solans A, Vives R, et al. Tolerability and pharmacokinetics of repeated doses of dersalazine sodium in healthy volunteers. Gastroenterology. 2010;138(suppl 1):S522. Abstract T1255.
15. Román J, Planell N, Lozano JJ, et al. Evaluation of responsive gene expression as a sensitive and specific biomarker in patients with ulcerative colitis. Inflamm Bowel Dis. 2013;19:221-229.
16. Rutgeerts P, Sandborn WJ, Feagan B, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. NEngl J Med. 2005;353:2462-2476.
17. Zimmerman HJ. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999;428-433.
18. Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010;16:338-346.
19. Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10:CD000543.
20. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146: 392-400.
21. Khan KJ, Dubinsky MC, Ford AC, et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and metaanalysis. Am J Gastroenterol. 2011;106:630-642.
22. Panés J, López-SanRomán A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology. 2013;145:766-774.
23. Avallone EV, Pica R, Cassieri C, et al. Azathioprine treatment in inflammatory bowel disease patients: type and time of onset of side effects. Eur Rev Med Pharmacol Sci. 2014;18:165-170.